immunodeficiency 74, COVID-19-related, X-linked

Summary

immunodeficiency 74, COVID-19-related, X-linked (MONDO:0026767) is a disease with 1 cohort gene.

At a glance

• Cohort genes: 1
• ClinVar variants: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	immunodeficiency 74, COVID-19-related, X-linked
Mondo ID	MONDO:0026767
OMIM	301051
DOID	DOID:0112063
UMLS	C5435745
MedGen	1768360
Is cancer (heuristic)	no

Also known as: IMD74 · immunodeficiency 74, COVID19-related, X-linked, X-linked recessive

Data availability: 5 ClinVar variants · 2 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › immunodeficiency disease › immunodeficiency 74, COVID-19-related, X-linked

Related subtypes (94): B cell deficiency, T-cell immunodeficiency, complement deficiency, myalgic encephalomeyelitis/chronic fatigue syndrome, hypoproteinemia, hypercatabolic, X-linked lymphoproliferative syndrome, Wiskott-Aldrich syndrome, autosomal dominant form, immunodeficiency due to CD25 deficiency, immunodeficiency 67, primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency, immunodeficiency 35, pyogenic bacterial infections due to MyD88 deficiency, lymphoproliferative syndrome 1, FADD-related immunodeficiency, immunodeficiency 31B, Wiskott-Aldrich syndrome 2, cryptosporidiosis-chronic cholangitis-liver disease syndrome, idiopathic CD4 lymphocytopenia, immunodeficiency 23, DOCK2 deficiency, immunodeficiency 45, TFRC-related combined immunodeficiency, combined immunodeficiency, autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome, immunodeficiency due to selective anti-polysaccharide antibody deficiency, immunodeficiency 57, immunodeficiency 14b, autosomal recessive, immunodeficiency 98 with autoinflammation, X-linked, immunodeficiency 102, immunodeficiency 66, immunodeficiency 80 with or without congenital cardiomyopathy, immunodeficiency 81, immunodeficiency 82 with systemic inflammation, immunodeficiency 84, immunodeficiency 85 and autoimmunity, immunodeficiency 86, immunodeficiency 87 and autoimmunity, immunodeficiency 88, immunodeficiency 89 and autoimmunity, immunodeficiency 91 and hyperinflammation, immunodeficiency 92, immunodeficiency 93 and hypertrophic cardiomyopathy, immunodeficiency 95, immunodeficiency 96, immunodeficiency 97 with autoinflammation, immunodeficiency 99 with hypogammaglobulinemia and autoimmune cytopenias, immunodeficiency 101 (varicella zoster virus-specific), immunodeficiency 75, immunodeficiency 76, immunodeficiency 106, susceptibility to viral infections, immunodeficiency 78 with autoimmunity and developmental delay, immunodeficiency 77, immunodeficiency 107, susceptibility to invasive staphylococcus aureus infection, immunodeficiency 15a, immunodeficiency 60, immunodeficiency 62, immunodeficiency 63 with lymphoproliferation and autoimmunity, immunodeficiency 64, immunodeficiency 65, susceptibility to viral infections, immunodeficiency 69, immunodeficiency 70, immunodeficiency 72 with autoinflammation, GATA2 deficiency with susceptibility to MDS/AML, Shwachman-Diamond syndrome 1, immunodeficiency 53, immunodeficiency 11b with atopic dermatitis, IKBKG-related immunodeficiency with or without ectodermal dysplasia, FNIP1-associated syndrome, FASLG-related immunodeficiency, TNFRSF9-related immunodeficiency, DNAJC21-related Shwachman Diamond syndrome, IRF4-related immune disorder, PTEN harmartoma tumor syndrome with immune disorder, primary immunodeficiency due to calcium channel deficiency, chronic mucocutaneous candidiasis and connective tissue disease due to JNK1 haploinsufficiency, immune deficiency due to impaired neutrophil phagocytosis and migration, hatipoglu immunodeficiency syndrome, immunodeficiency 112, immunodeficiency 113 with autoimmunity and autoinflammation, immunodeficiency 114, folate-responsive, immunodeficiency 115 with autoinflammation, immunodeficiency 117, immunodeficiency 118, immunodeficiency 119, immunodeficiency 121 with autoinflammation, immunodeficiency 122, immunodeficiency 123 with HPV-related verrucosis, immunodeficiency 125, immunodeficiency 126, susceptibility to, immunodeficiency 127, immunodeficiency 128, immunodeficiency 132b, immunodeficiency 133 with ectodermal dysplasia with or without peripheral neuropathy, immunodeficiency 134 (Epstein-Barr virus-specific)

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

5 retrieved; paginated sample, class counts are floors:

2 uncertain significance, 2 pathogenic, 1 likely pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
977232	NM_016562.4(TLR7):c.2129_2132del (p.Gln710fs)	TLR7	Pathogenic	no assertion criteria provided
977233	NM_016562.4(TLR7):c.2383G>T (p.Val795Phe)	TLR7	Pathogenic	no assertion criteria provided
4813714	NM_016562.4(TLR7):c.995del (p.Asp332fs)	TLR7	Likely pathogenic	criteria provided, single submitter
2076929	NM_016562.4(TLR7):c.943A>C (p.Lys315Gln)	TLR7	Uncertain significance	criteria provided, multiple submitters, no conflicts
4845371	NM_016562.4(TLR7):c.1643A>C (p.Asp548Ala)	TLR7	Uncertain significance	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 5 · Orphanet: 1 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
TLR7	Moderate	X-linked	immunodeficiency 74, COVID-19-related, X-linked	5

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
TLR7	Orphanet:536	Systemic lupus erythematosus

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
TLR7	HGNC:15631	ENSG00000196664	Q9NYK1	Toll-like receptor 7	gencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
TLR7	Toll-like receptor 7	Endosomal receptor that plays a key role in innate and adaptive immunity.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Other/Unknown	1	1.8×	0.558

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
TLR7	Other/Unknown	no		TIR_dom, Cys-rich_flank_reg_C, Leu-rich_rpt

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
leukocyte	1
monocyte	1
mononuclear cell	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
TLR7	163	broad	marker	monocyte, mononuclear cell, leukocyte

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
TLR7	4,103

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
TLR7	Q9NYK1	1

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 11. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Defective regulation of TLR7 by endogenous ligand	1	11420.0×	1e-03	TLR7
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling	1	878.5×	0.004	TLR7
Trafficking and processing of endosomal TLR	1	815.7×	0.004	TLR7
Regulation of TLR by endogenous ligand	1	496.5×	0.006	TLR7
SARS-CoV-1 activates/modulates innate immune responses	1	271.9×	0.007	TLR7
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	1	190.3×	0.007	TLR7
MyD88 dependent cascade initiated on endosome	1	190.3×	0.007	TLR7
Toll Like Receptor 7/8 (TLR7/8) Cascade	1	184.2×	0.007	TLR7
RSV-host interactions	1	156.4×	0.008	TLR7
Potential therapeutics for SARS	1	114.2×	0.010	TLR7
SARS-CoV-2 activates/modulates innate and adaptive immune responses	1	89.2×	0.011	TLR7

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
response to cGMP	1	8426.0×	0.002	TLR7
toll-like receptor 8 signaling pathway	1	5617.3×	0.002	TLR7
toll-like receptor 7 signaling pathway	1	3370.4×	0.002	TLR7
positive regulation of macrophage cytokine production	1	732.7×	0.006	TLR7
positive regulation of interferon-alpha production	1	648.1×	0.006	TLR7
toll-like receptor signaling pathway	1	601.9×	0.006	TLR7
positive regulation of interferon-beta production	1	391.9×	0.006	TLR7
positive regulation of chemokine production	1	374.5×	0.006	TLR7
canonical NF-kappaB signal transduction	1	366.4×	0.006	TLR7
JNK cascade	1	271.8×	0.007	TLR7
positive regulation of interleukin-8 production	1	244.2×	0.007	TLR7
positive regulation of type II interferon production	1	224.7×	0.007	TLR7
cellular response to mechanical stimulus	1	216.1×	0.007	TLR7
cellular response to virus	1	200.6×	0.007	TLR7
positive regulation of interleukin-6 production	1	166.8×	0.008	TLR7
positive regulation of inflammatory response	1	145.3×	0.009	TLR7
positive regulation of canonical NF-kappaB signal transduction	1	72.6×	0.017	TLR7
defense response to virus	1	69.3×	0.017	TLR7
inflammatory response	1	37.7×	0.029	TLR7
innate immune response	1	33.6×	0.031	TLR7
positive regulation of transcription by RNA polymerase II	1	14.9×	0.067	TLR7

Therapeutics

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 0

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
TLR7	IMIQUIMOD

Top cohort targets by molecule count

Symbol	Molecules	Max phase
TLR7	9	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
IMIQUIMOD	4	TLR7
HYDROXYCHLOROQUINE	4	TLR7
VESATOLIMOD	2	TLR7
RESIQUIMOD	2	TLR7
GSK-2245035	2	TLR7
AFIMETORAN	2	TLR7
MHV-370	2	TLR7
CPG-52852	2	TLR7
GURETOLIMOD	1	TLR7

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
TLR7	356	Binding:321, Functional:35

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
TLR7	356

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

9 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
IMIQUIMOD	4	TLR7
HYDROXYCHLOROQUINE	4	TLR7
VESATOLIMOD	2	TLR7
RESIQUIMOD	2	TLR7
GSK-2245035	2	TLR7
AFIMETORAN	2	TLR7
MHV-370	2	TLR7
CPG-52852	2	TLR7
GURETOLIMOD	1	TLR7

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	TLR7
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 0.